Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Myslowice

45 clinical trials in Myslowice, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Myslowice at a glance
45
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

45 trials in Myslowice

Open in trial search

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Metabolic dysfunction-associated liver disease

Recruiting

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Hepatic cirrhosis

Recruiting

Study of Pegozafermin Treatment for Patients with Liver Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Autoimmune hepatitis

Recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Cholangitis sclerosing

Recruiting

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Primary biliary cholangitis

Recruiting

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Alpha-1 antitrypsin deficiency

Recruiting

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Myslowice

What the registry says about research in the country

01 Liver Disease Studies

Groundbreaking research focusing on Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis, evaluating novel therapeutic approaches and treatments. Studies are examining the safety and efficacy of experimental medications for these chronic liver conditions.

  • Cholangitis treatments
  • Liver fibrosis management
  • Chronic liver disease therapy
02 Cancer Research

Advanced clinical trials investigating treatments for Hepatocellular Carcinoma and Non-Muscle Invasive Bladder Cancer. Studies are evaluating combination therapies and immunotherapy approaches to improve patient outcomes.

  • Liver cancer treatments
  • Bladder cancer therapies
  • Immunotherapy studies
03 Metabolic Disorders

Innovative research on Type 2 Diabetes Mellitus and Non-alcoholic Steatohepatitis (NASH). Studies are exploring new combination therapies and investigating treatments for liver complications associated with metabolic conditions.

  • Diabetes management
  • NASH treatments
  • Metabolic disease therapy
Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.